Organization
Prevail Therapeutics
4 clinical trials
Clinical trial
A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients With Fronto-Temporal Dementia With Progranulin Mutations (FTD-GRN)Status: Recruiting, Estimated PCD: 2029-08-31
Clinical trial
An Open-label, Dose-Finding, Phase 1/2 Study to Evaluate the Safety and Tolerability of a Single Intravenous Dose of LY3884961 in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)Status: Recruiting, Estimated PCD: 2030-10-02
Clinical trial
A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)Status: Recruiting, Estimated PCD: 2029-06-01
Clinical trial
An Open-label, Phase 1/2 Study to Evaluate the Safety and Efficacy of Single-dose LY3884961 in Infants With Type 2 Gaucher DiseaseStatus: Active (not recruiting), Estimated PCD: 2028-05-01